The pivotal role of the RANKL-RANK pathway in bone physiology and pathology led to the development of denosumab, a fully human anti-RANKL monoclonal antibody currently approved for the treatment of bone remodeling diseases, including cancer-induced bone metastases [108, 109]. Here, TNFSF11 is linked to bone remodeling disease.